Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,603 | 8 | 66.2% |
| Unspecified | $4,389 | 6 | 33.8% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $10,961 | 10 | $0 (2020) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $1,508 | 2 | $0 (2018) |
| F. Hoffmann-La Roche AG | $522.04 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $1,355 | 3 | Genentech, Inc. ($832.50) |
| 2019 | $2,220 | 2 | Genentech, Inc. ($2,220) |
| 2018 | $6,066 | 6 | Genentech, Inc. ($5,550) |
| 2017 | $3,351 | 3 | Genentech, Inc. ($2,359) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $343.46 | Research |
| Study: Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children • Category: BioOncology | ||||||
| 04/14/2020 | Genentech, Inc. | COTELLIC (Drug) | Consulting Fee | Cash or cash equivalent | $832.50 | General |
| Category: BioOncology | ||||||
| 03/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $178.58 | Research |
| Study: A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions • Category: BioOncology | ||||||
| 10/01/2019 | Genentech, Inc. | COTELLIC (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: BioOncology | ||||||
| 03/19/2019 | Genentech, Inc. | COTELLIC (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: BioOncology | ||||||
| 09/12/2018 | Genentech, Inc. | COTELLIC (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: BioOncology | ||||||
| 06/02/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | MEKINIST (Drug) | — | In-kind items and services | $516.00 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: ONCOLOGY | ||||||
| 04/23/2018 | Genentech, Inc. | COTELLIC (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: BioOncology | ||||||
| 04/23/2018 | Genentech, Inc. | COTELLIC (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: BioOncology | ||||||
| 04/05/2018 | Genentech, Inc. | COTELLIC (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: BioOncology | ||||||
| 04/02/2018 | Genentech, Inc. | COTELLIC (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: BioOncology | ||||||
| 12/07/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | TAFINLAR (Drug) | — | In-kind items and services | $992.11 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: ONCOLOGY | ||||||
| 10/18/2017 | Genentech, Inc. | COTELLIC (Drug) | — | Cash or cash equivalent | $1,526.25 | Research |
| Study: OPEN LABEL STUDY OF COBIMETINIB IN PAEDIATRIC PATIENTS WITH R R SOLID TUMORS • Category: BioOncology | ||||||
| 10/18/2017 | Genentech, Inc. | COTELLIC (Drug) | — | Cash or cash equivalent | $832.50 | Research |
| Study: OPEN LABEL STUDY OF COBIMETINIB IN PAEDIATRIC PATIENTS WITH R R SOLID TUMORS • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OPEN LABEL STUDY OF COBIMETINIB IN PAEDIATRIC PATIENTS WITH R R SOLID TUMORS | Genentech, Inc. | $2,359 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,508 | 2 |
| Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children | F. Hoffmann-La Roche AG | $343.46 | 1 |
| A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions | F. Hoffmann-La Roche AG | $178.58 | 1 |
About Dr. Christine Pratilas, MD
Dr. Christine Pratilas, MD is a Pediatrics healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336204445.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christine Pratilas, MD has received a total of $12,991 in payments from pharmaceutical and medical device companies, with $1,355 received in 2020. These payments were reported across 14 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($8,603).
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Hematology-Oncology, Pediatric Hematology-Oncology
- Location Baltimore, MD
- Active Since 12/27/2006
- Last Updated 03/30/2023
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1336204445
Products in Payments
- COTELLIC (Drug) $10,961
- TAFINLAR (Drug) $992.11
- ROZLYTREK (Biological) $522.04
- MEKINIST (Drug) $516.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Baltimore
Harry Dietz, M.d, M.D
Pediatrics — Payments: $1.3M
Kenneth Cooke, Md, MD
Pediatrics — Payments: $397,951
Julie Hoover-Fong, M.d, M.D
Pediatrics — Payments: $209,959
Carmelo Cuffari, M.d, M.D
Pediatrics — Payments: $105,979
Dr. M. Elizabeth Younger, Cpnp, CPNP
Pediatrics — Payments: $101,884
Dr. Errol Fields, Md, Phd, Mph, MD, PHD, MPH
Pediatrics — Payments: $45,921